The Pharma Letter7d
BRIEF—Mexican approval for Alzheimer’s drug Leqembi
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the ...
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Yahoo Finance7d
Leqembi® approved in Mexico
STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk ...
Eisai, Biogen say LEQEMBI approved for treatment of early AD in Mexico
Eisai (ESALY) and Biogen (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved humanized ...
Eisai And Biogen : Mexico Approves LEQEMBI For Early Alzheimer's Disease Treatment
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...
Pharmabiz6d
Mexican health authority approves Leqembi for the treatment of early Alzheimer’s disease
Mexican health authority approves Leqembi for the treatment of early Alzheimer’s disease: Tokyo Friday, December 6, 2024, 14:00 Hrs [IST] Eisai Co., Ltd. and Biogen Inc. announc ...
Nasdaq7d
Eisai, Biogen say LEQEMBI approved for treatment of early AD in Mexico
Eisai (ESALY) and Biogen (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved humanized anti-soluble aggregated amyloid-beta monoclonal ...
Medindia8d
Leqembi® approved in Mexico
STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) ...